Compare UNTY & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UNTY | CTNM |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.4M | 489.4M |
| IPO Year | 2014 | 2024 |
| Metric | UNTY | CTNM |
|---|---|---|
| Price | $57.73 | $13.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $65.00 | $19.00 |
| AVG Volume (30 Days) | 54.2K | ★ 512.7K |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ 39.66 | 0.46 |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.14 | N/A |
| Revenue Next Year | $9.56 | N/A |
| P/E Ratio | $41.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.34 | $4.76 |
| 52 Week High | $60.86 | $16.91 |
| Indicator | UNTY | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 47.22 |
| Support Level | $50.54 | $11.73 |
| Resistance Level | $60.86 | $15.60 |
| Average True Range (ATR) | 1.97 | 1.06 |
| MACD | -0.07 | -0.17 |
| Stochastic Oscillator | 63.05 | 10.04 |
Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. The Company has elected to become a financial holding company pursuant to regulations of the Board of Governors of the Federal Reserve System (the FRB). The Company's primary business is ownership and supervision of the Bank. The Company and the Bank derive a majority of their revenue from net interest income (i.e., the difference between the interest received on loans and securities and the interest paid on deposits and borrowings). The Company, through the Bank, conducts a traditional and community-oriented commercial banking business and services, personal and business checking accounts, time deposits, money market accounts, savings accounts, credit cards, automated teller service, and others.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.